染料木素对去势大鼠骨质疏松和甲状旁腺激素受体1的作用研究
|
摘要
绝经后骨质疏松(Postmenopausal Osteoporosis, PMO)在骨质疏松(osteoporosis,OP)中占有相当大的比例,具有较高的发病率,严重影响中老年妇女的生活质量。较长时期以来,PMO的预防和治疗都以雌激素替代疗法(Hormone replacement therapy)为主。但是伴随HRT的长期使用不断出现的性腺肿瘤发病率增高等副作用使其应用受到质疑和限制。开发和研究选择性雌激素受体调节剂(SERMs)引起了人们极大的兴趣,很多SERMs(如他莫昔芬和雷洛昔芬)开始用于临床。但长期使用这些药物仍会出现一些不良反应,如他莫昔芬会增加子宫癌、潮热、血栓;雷洛昔芬除了存在恶心、潮热、头痛、乳房肿痛等常见副作用外,还会引起深静脉血栓栓塞,故不适用于有血管舒缩症状的绝经后妇女。因此,寻找选择性更好、作用更强、副作用更少的防治PMO药物是目前的研究热点。其中,染料木素(Gen)是重要的异黄酮类植物雌激素;它具有与雌激素类似结构和温和的雌激素样生物活性。体内外研究结果均显示染料木素具有明显骨保护作用,能够促进成骨细胞(Osteoblast ,OB)的增殖和分化;在动物模型上,染料木素能够有效地缓解去势引起的骨密度降低。
甲状旁腺激素(Parathyroid hormone,PTH)是调节钙磷代谢、维持机体钙平衡的主要激素,其主要的靶器官是骨骼和肾脏,并且在肾和骨骼中呈高表达。研究发现PTH相关蛋白能有效地促进骨骼合成,并且PTH和PTH相关蛋白能作用于相同的受体,即PTH受体1。目前,有关PMO患者体内甲状旁腺激素受体1(Parathyroid hormone receptorⅠ,PTHR1)与正常者的比较研究尚未见报道。
本实验采用去势法建立雌性大鼠骨质疏松模型,观察去势大鼠骨质疏松股骨生物力学和骨密度的改变,同时检测股骨中PTHR1基因和蛋白水平,首次探讨PTHR1对去势诱发骨质疏松影响的重要意义。并在此基础上,我们对各组大鼠给予大中小剂量染料木素干预,设立对照组并在基因和蛋白水平检测股骨中PTHR1的表达水平。研究证明染料木素组动物的PTHR1表达水平较模型组动物明显上调,这提示染料木素治疗PMO过程中,PTHR1受体可能是其中的一种作用途径。
Postmenopausal osteoporosis (PMO) at the OP plays a large proportion of high morbidity and mortality in old women seriously affect the quality of life. A longer period of time, PMO prevention and treatment are hormone replacement therapy (HRT)-oriented. However,long-term use of HRT associated with the continuing occurrence of side effects of its application has been questioned and restrictions. Development and research of selective estrogen receptor modulators (SERMs) has aroused great interest, a lot of SERMs (such as tamoxifen and raloxifene) and for clinical. At the same time, long-term use of these drugs will still be some adverse reactions, such as: tamoxifen will increase uterine cancer, hot flashes, the incidence of thrombosis; raloxifene exists apart from nausea, hot flashes, headache, breast pain, such as regular side-effects, but also caused by deep venous thrombo-embolism, it does not apply to have vasomotor symptoms in postmenopausal women. Therefore , selectively researching better, stronger, fewer side-effects of drug prevention and treatment of PMO is to study one of the hotspots. One of the main categories is the one source of isoflavones plants. Genistein (Gen) is an important phytoestrogen. It has a similar structure estrogen and mild estrogen-like biological activity. In vivo and in vitro studies have shown that Gen has a bone protective effect, can promote the proliferation and differentiation of OB. In animal model, Gen can effectively alleviate the castration caused by reduced bone mineral density.
Parathyroid hormone (PTH, Parathyroid hormone) regulate calcium metabolism, calcium balance to maintain the body's main hormone, its main target organs are bone and kidney. And it showed high expression in bone. Study found that PTH-related protein can effectively promote bone synthesis, and PTH and PTH-related protein can act on the same receptor, namely PTH receptor 1. At present, the patient PMOP parathyroid hormone receptor 1 (PTHR1), compared with the normal existence of differences has not been reported.
Firstly,we set up the experiment using ovariectomized female rat model of osteoporosis was observed in rats ovariectomized osteoporosis femur biomechanics and bone mineral density changes in femoral. Detect PTHR1 gene and protein level to explore the PTHR1 on castration-induced osteoporosis the importance of osteoporosis. And on this basis, we given doses of genistein to rats, the establishment of the control group,and at the level of gene and protein detection femur in the expression level of PTHR1. The results show that genistein group PTHR1 expression level is significantly increases, compared to the blank model group, which suggests that genistein treatment PTHR1 receptors are one of the possible ways at PMO process.
甲状旁腺激素(Parathyroid hormone,PTH)是调节钙磷代谢、维持机体钙平衡的主要激素,其主要的靶器官是骨骼和肾脏,并且在肾和骨骼中呈高表达。研究发现PTH相关蛋白能有效地促进骨骼合成,并且PTH和PTH相关蛋白能作用于相同的受体,即PTH受体1。目前,有关PMO患者体内甲状旁腺激素受体1(Parathyroid hormone receptorⅠ,PTHR1)与正常者的比较研究尚未见报道。
本实验采用去势法建立雌性大鼠骨质疏松模型,观察去势大鼠骨质疏松股骨生物力学和骨密度的改变,同时检测股骨中PTHR1基因和蛋白水平,首次探讨PTHR1对去势诱发骨质疏松影响的重要意义。并在此基础上,我们对各组大鼠给予大中小剂量染料木素干预,设立对照组并在基因和蛋白水平检测股骨中PTHR1的表达水平。研究证明染料木素组动物的PTHR1表达水平较模型组动物明显上调,这提示染料木素治疗PMO过程中,PTHR1受体可能是其中的一种作用途径。
Postmenopausal osteoporosis (PMO) at the OP plays a large proportion of high morbidity and mortality in old women seriously affect the quality of life. A longer period of time, PMO prevention and treatment are hormone replacement therapy (HRT)-oriented. However,long-term use of HRT associated with the continuing occurrence of side effects of its application has been questioned and restrictions. Development and research of selective estrogen receptor modulators (SERMs) has aroused great interest, a lot of SERMs (such as tamoxifen and raloxifene) and for clinical. At the same time, long-term use of these drugs will still be some adverse reactions, such as: tamoxifen will increase uterine cancer, hot flashes, the incidence of thrombosis; raloxifene exists apart from nausea, hot flashes, headache, breast pain, such as regular side-effects, but also caused by deep venous thrombo-embolism, it does not apply to have vasomotor symptoms in postmenopausal women. Therefore , selectively researching better, stronger, fewer side-effects of drug prevention and treatment of PMO is to study one of the hotspots. One of the main categories is the one source of isoflavones plants. Genistein (Gen) is an important phytoestrogen. It has a similar structure estrogen and mild estrogen-like biological activity. In vivo and in vitro studies have shown that Gen has a bone protective effect, can promote the proliferation and differentiation of OB. In animal model, Gen can effectively alleviate the castration caused by reduced bone mineral density.
Parathyroid hormone (PTH, Parathyroid hormone) regulate calcium metabolism, calcium balance to maintain the body's main hormone, its main target organs are bone and kidney. And it showed high expression in bone. Study found that PTH-related protein can effectively promote bone synthesis, and PTH and PTH-related protein can act on the same receptor, namely PTH receptor 1. At present, the patient PMOP parathyroid hormone receptor 1 (PTHR1), compared with the normal existence of differences has not been reported.
Firstly,we set up the experiment using ovariectomized female rat model of osteoporosis was observed in rats ovariectomized osteoporosis femur biomechanics and bone mineral density changes in femoral. Detect PTHR1 gene and protein level to explore the PTHR1 on castration-induced osteoporosis the importance of osteoporosis. And on this basis, we given doses of genistein to rats, the establishment of the control group,and at the level of gene and protein detection femur in the expression level of PTHR1. The results show that genistein group PTHR1 expression level is significantly increases, compared to the blank model group, which suggests that genistein treatment PTHR1 receptors are one of the possible ways at PMO process.
引文
1.刘忠厚,主编.骨质疏松症.北京:科学出版社,1998: 87-90;131
2.邓廉夫.骨质疏松发生的细胞学基础及其防治.实用老年医学,2000: 14(3):119-121
3. Friedenstein AJ. Precursor cells of mechanocytes. Int Rev Cytol 1976; 47(3):327-59
4. Benayahu D, KletterY Zipori D, Wientroub S. Bone marrow-derived stromal cell line expressing osteoblastic phenotype in vitro and osteogenic capacity in vivo. J Cell Physiol 1989; 140(1):1-7
5. Aronow MA, Gerstenfeld LC, Owen TA, Tassinari MS, Stein GS, Lian JB.Factors that promote progressive development of the osteoblast phenotype in cultured fetal rat calvaria cells. J Cell Physiol 1990; 143(2):213-21
6. Lomri A, Marie PJ, Tran PV,Hott M. Characterization of endosteal osteoblastic cells isolated from mouse caudal vertebrae. Bone 1988; 9(3):165-75
7. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332(5):305-11
8. Zheng MH, Wood DJ, Papadimitrion JM.What's new in the role of cytokineson osteoblast proliferation and differentiation? Pathol Res Pract 1992; 188(8):1104-21
9.童安莉,陈璐璐,丁桂芝.成骨细胞骨形成机制研究进展.中国骨质疏松杂志,1999; 5(3): 60-64
10. McCabe LR, Last TJ, Lynch M, Lian J, Stein J, Stein G Expression of cellgrowth and bone phenotypic genes during the cell cycle of normal diploid osteoblasts and osteosarcoma cells. J Cell Biochem 1994 ;56(2):274-82
11. Lynch MP, Capparelli C, Stein JL, Stein GS, Lian JB. Apoptosis during bone-like tissue development in vitro. J Cell Biochem 1998; 68(1):31-49
12. Zheng Nicholson GC, Warton A, Papadimitriou JM. What's new inosteoclast ontogeny? Pathol Res Pract 1991;187(1):117-25
13. Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K , Chesnut H 3rd. Long term calcitonin therapy in postmenopausal osteoporosis.Metabolisml 1984; 33(4):295-303
14. Barrett-Connor E. Epidemiology and the menopause: a global overview. Int JFertil Menopausal Stud 1993; 38 Suppl 1:6-14
15.李恩.原发性骨质疏松发病的相关因素.中国骨质疏松杂志,1997, 3 (2):1-3
16. Morel G , Boivin G , David L , Dubois PM , Meunier PJ. Immunocytochemical vidence for endogenous calcitonin and parathyroid hormone in osteoblasts from he calvaria of neonatal mice. Absence of endogenous estradiol and estradiol eceptors. Cell Tissue Res 1985;240(1):89-93
17. Pensler JM, Radosevich JA, Higbee R, Langman CB. Osteoclasts isolated rom membranous bone in children exhibit nuclear estrogen and progesterone eceptors. J Bone Miner Res 1990; 5(8):797-802
18.徐叔云,卞如镰主编.药理实验方法学。人民卫生出版社,1991年第二版,p1293
19. Kameda T, Mano H, Yuasa T, Mori Y, Miyazawa K, Shiokawa M, Nakamaru Y, Hiroi E, Hiura K, Kameda A, Yang NN, HakedaY, Kumegawa M. Estrogeninhibits bone resorption by directly inducing apoptosis of the bone-resorbing steoclasts. J Exp Med 1997 , 18 ; 186(4):489-95
20.任莉,陈阳生,催翠云.骨质疏松症的药物治疗.中国骨质疏松杂志2005,11(1):126-9
21. Rossouw J.E., Anderson GL., Prentice R.L. et al., Risks and benefits of strogen plus progestin in healthy postmenopausal women: principal results from he women's health initiative randomized controlled trial. J Am Med Assoc 2002;( 288):321-33
22. Elisabeth Sornay-Rendu, Patrick Garnero, Franc, Oise Munoz, Franc, ois uboeuf , Pierre D. Delmas. Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study. Bone 2003; 33(1):159-66
23. Boukes FS, Groeneveld, assendelft WJ. Summary or the DCGP practiceguideline "the menopause". Ned Tijdschr Geneeskd 2002 ; 146(28):1317-20
24. Neves-e-Castro M, Samsioe C, Dorm M, O Skouby S; European Menopause&Andropause Society. Results from WHI and HERS II一Implications for women and the prescriber of HRT. Maturitas 2002; 42(4):255-258
25.林华.骨质疏松临床治疗的选择与实施-骨质疏松的个体化治疗.国外医学内分泌学分册,2003,23 C2): 101-103
26.朱静芬,谢庆文,杨永彬.绝经后骨质疏松症药物预防和治疗方案分析.中国临床康,2005, 9 (11): 148-149
27. Alexandersen P, Toussaint A, Christiansen C, Devogelaer JP, Roux C,Fechtenbaum J, Gennari C, Reginster JY; Ipriflavone Multicenter European Fracture Study. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA 2001; 285(11):1482-8
28. Sogaard CH, Mosekilde L, Schwartz W, Leidig C; Minne HW, Ziegler R.Effects of fluoride on rat vertebral body biomechanical competence and bone mass. Bone 1995;16(1):163-9
29. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;3 59(9322): 2018-2026
30. Dambacker,Schacht(朱汉民译).骨质疏松和活性维生素D进展.Dasle, Switzerland: EULAR publisher,1996
31.谭世桥,唐晓红钙剂在绝经后骨质疏松防治中的作用,中国临床康复,2004,8(3):541
32. Sairanen S, Karkkainen M, Tahtela R, Laitinen K, Makela P,Lamberg-Allardt C, Ualimaki MJ. Bone mass and markers of bone and calcium metabolism in postmenopausal women treated with 1 , 25-dihydroxy vitamin D for four years. Calcif Tissue Int 2000; 67(2): 122-7
33. Raisz LG Bone cell biology: new approaches and unanswered queations. J Bone Miner Res 1993; 8 (Suppl 2): 5457-65
34. Santell RC, Chang YC, Nair Mq Helferich WG Dietary genistein exerts estrogenic effects upon the uterus , mammary gland and the hypothalamic/pituitary axis in rats. J Nutr 1997; 127(2):263-9
35. Anthony MS,Clarkson TB, Hughes CL. Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal rhesus monkeys. J Nutri 1996; 126(1):43-50
36. Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW Jr. Soy protein and isoflavones: their effects on blood lipids and bone density in. Am J Clin Nutri 1998; 68(6 suppl):1375S-9S
37. Naaz A, Yellayi S, Zakroczymski MA, Bunick D, Doerge DR, Lubahn DB, Helferich Wq Cooke PS. The soy isoflavone genistein decreases adipose deposition in mice, Endocrinology 2003; 144 (8):3315-20
38. Sirtori CR,Lovati MR,Manzoni C. Soy and cholesterol resuction: clinical experience. JNutr 1995; 125(3suppl):5985-6055
39. Kanazawa T,Osanai T,Zhang Xs.Protective effects of soy protein on the peroxidizability of lipoproteins in cerebro-vascular diseases.Nutr 1995;125 (3 suppl):6395-46S
40. Fotsis T, Pepper M, Adlercreutz H. Genistein a dietaryderived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 1993; 90(7): 2690-4
41. Murphy CT, Kellie S, Westwick J. Tyrosine-Kinase activity in rabbit platelets stimulated with platelet-activating factor: The effect of inhibiting tyrosine kinase with genistein on platelet-signal-molecule elevation and function responses. Eur J Biochem 1993; 216(2):639-51
42. Blair HC, Jordan SE, Peterson TC} Barnes S. Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats. J cell Biochem 1996; 61(4):629-637
43. Fanti P, Monier-Faugere MC, Geng Z, Schmidt J, Morris PE, Cohen D, Malluche HH.The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats. Osteoporos Int 1998; 8(3):274-81
44. Yamaguchi M, Sugimoto E. Stimulatory effect of genistein and daidzein on protein synthesis in osteoblastic MC3T32E1 cells: activation of amino acyl tRNA synthetase. Mol Cell Biochem 2000; 214(122): 97-102
45. Mori M, Aizawa T, Tokoro M, Mild T, Yamori Y Soy isoflavone tablets reduce osteoporosis risk factors and obesity in middle-aged Japanese women. Clin Exp Pharmacol Physiol 2004; 31(suppl 2): 539-41
46. Gikas PD, Mokbel K. Phytoestrogens and the risk of breast cancer: a review of the literature. Int J Fertil Womens Med 2005; 50(6):250-258
47. Guo JM, Xiao BX, Liu DH, Grant M, Zhang S, Lai YF, Guo YB, Liu Q.Biphasic effect of daidzein on cell growth of human colon cancer cells. Food Chem Toxicol 2004; 42(10):1641-6
48. Wangen KE, Duncan AM, Merz-Demlow BE. Effects of soy isoflavones on markers of bone turnover in premenopausal and post menopausal women. Clin Endocr 2000; 85(9): 3043-3048
49. Branca F. Dietary phyto-oestrogens and bone health. Proc Nutr Soc 2003; 62(4): 877-87
50.谢煌,姚珍薇.维生素K、雌激素和骨质疏松实用老年医学,2006, 20(5):347-349
51. IshimiY Arai N, Wang X, Wu J, Umegaki K, Miyaura C, Takeda A, Ikegami S. Difference in effective dosage of genistein on bone and uterus in ovariectomized mice. Biochem Biophys Res Commun 2000; 274(3):697-701
52. Naaz A, Yellayi S, Zakroczymski MA, Bunick D, Doerge DR, Lubahn DB,Helferich Wq Cooke PS. The soy isoflavone genistein decreases adipose deposition in mice. Endocrinology. 2003; 144(8):3315-20
53. Alekel DL, Germain AS, Peterson CT. Isoflavoen-rich soy protein isolate attenuates bone loss in lumbar spine of perimenopausaol women. Am J Clin Nutr 2000; 72(3): 844-852
54. Morabito N, Crisafulli A, Vergara C, Gaudio A, Lasco A, FrisinaN, D'Anna R, Corrado F, Pizzoleo MA, Cincotta M, Altavilla D, Ientile R, Squadrito F. Effects of genistein and hormone-replacement therapy on bone loss n early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res 2002 ; 17(10):1904-12
55. Chiechi LM, Secreto qD'Amore M, Fanelli M, Venturelli E, Cantatore F, Ualerio T, Laselva C; Loizzi P. Efficacy of a soy rich diet in preventing postmenopausal osteoporosis:the menfis randomized trial. Maturitas 2002; 42(4):295-300
56. Dalais FS, Ebeling PR, Kotsopoulos D, McGrath BP, Teede HJ. The effects of soy protein containing isoflavones on lipids and indices of bone resorption in post-menopausal women. Clin Endocrinol (Oxf) 2003; 58(6):704-9
57. Gronwald W,Schomburg D,Harder MP,et al. Structure of re2 combinant human parathyroid hormone in solution using multidi2 mensional NMR spectroscopy [J] . Biol Chem Hoppe Seyler,1996,377 (3):175
58. Schievano E,Mammi S,Silvestri L,et al.Conformational studies of parathyroid hormone ( PTH) / PTH 2related protein(PTHrP) chimeric peptides [J] . Biopolymers,2000,54 ( 7):429
59. 0ldenburg KR,Epand RF,Dorfani A,et al . Conformational studies on analogs of recombinant parathyroid hormone and their interations with phospholipids[ J] . Biolchem,1996,271 (299) :17582
60. Reidhaar Olson J F,Davis RM,De Souza Hart JA,et al.Active variants of human parathyroid (1234) with multiple amino acid substitutions[J].Mol Cell Endocri nol,2000,160 (122):135
61. Schwietert HR,Groen EW, Sollie FA,et al. Single2does sub2 cutaneousadministration of recombinant humanparathyorid hor2 mone [rhPTH(1～84)] in healthy postmenopausal volunteers[J].Cli nical Pharmacology and Therapeutics ,1997 ,61(3) :360
62. Boly J J.Gaich G A,Scheele W H,et al.A randomized doubleblind trial to compare the efficacy of teriparatide(PTH1-34) with alendronate in postmenopausal women with osteoporosis[J].J Clin Endlocrinol Metab,2002,87(10):4528
63. Urena P,Kong XF ,Abou-Samra AB, et al .Parathyroid hormone (PTH)/PTH-related peptidereceptor messenger ribonucleic acids are widely distributed in rat tissues[J].Endocrinology,1993,133:617-623
64. Perry HM 3rd, Chappel JC,Bellorin-Font E,et al. Parathyroid hormone receptors in circulating human mononuclear leukocytes[J].J Biol Chem,1984,259:5531-5535
65. Khafif A,Pivoarov A,Medina JE,et al .Parathyroid hormone:A sensitive predictorof hypocalcemia following total thyroidectomy[J]. Otolaryngol Head Neck Surg,2006,134:907-910.
66. Yu XP,Chandrasekhar S.Parathyroid hormone(PTH1–34) regulation OC of rat gene transcription[J].J Endocrinology,1997,138:3085-3092
67.洪燕,程义勇,张月红,等.钙缺乏对大鼠骨骼发育的影响及其机制探讨[J].卫生研究,2002,31:41-43
68. John T Potts. Parathyroid hormone: past and present[J]. Endocrinology,2005,187,311-325
69. Okazaki R,Inoue D,Shibata M, et al. Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta. Endocrinology. 2002 Jun;143(6):2349-2356
70.李凤英,王锦.甲状旁腺激素与骨质疏松,天津医科大学学报.2000,6(2):246-248
71. Urena P.Kong XF,Abous-Samra AB,et a1.Parathyoid hormone(PTH)/PTH-related peptidereceptor messenger ribonucleic acid are widely distributed in rattissue.Endocrinology,1993,133:6l7-623
72.徐进,荣海钦,季虹等.甲状旁腺激素相关蛋白治疗去卵巢大鼠骨质疏松的实验研究,中华风湿病杂志,2006, 10(3):154-157
73.王莹,杨淑霞.小鼠毛发周期中甲状旁腺激素受体mRNA表达的研究,中华皮肤科杂志.2002,35(2):147-148
74. Yokose S,Ishizuya T,Ikeda T,et al.An estrogen deficiency caused by ovariectomy increases plasma levels of systemic factors that stimulate proliferation and differentiation of osteoblasts in rats.Endocrinology,1996,137(2) : 469-478
75. Miao D, He B, Karaplis AC, Goltzman D,et al. Parathyroid hormone is essential for normal fetal bone formation. J Clin Invest. 2002 May;109(9):1173-1182
76. Schipani E,Karga H,Karaplis A C,et al. Identical complementary deoxyribonucleic acids encode a human renal and bone parathyroid hormone (PTH)/PTH-related peptide receptor. Endocrinology. 1993; 132: 2157-2165
77. Schipani E, Langman C, Hunzelman J, et al. A novel parathyroid hormone (PTH)/PTH-related peptide receptor mutation in Jansen's metaphyseal chondrodysplasia. J. Clin. Endocr. Metab. 1999 ; 84: 3052-3057
78. Parfitt A M,Schipani E,Rao D S,et al. Hypercalcemia due to constitutive activity of the parathyroid hormone (PTH)/PTH-related peptide receptor:comparison with primary hyperpara-thyroidism. J. Clin. Endocr. Metab. 1996; 81: 3584-3588
79. Jobert A-S,Zhang P, Couvineau A, et al. Absence of functional receptors for parathyroid hormone and parathyroid hormone-related peptide in Blomstrand chondrodysplasia. J. Clin. Invest.1998;102: 34-40
80. Hopyan S,Gokgoz N,Poon R,et al. A mutant PTH/PTHrP type I receptor in enchondromatosis. Nature Genet. 2002;30: 306-310
2.邓廉夫.骨质疏松发生的细胞学基础及其防治.实用老年医学,2000: 14(3):119-121
3. Friedenstein AJ. Precursor cells of mechanocytes. Int Rev Cytol 1976; 47(3):327-59
4. Benayahu D, KletterY Zipori D, Wientroub S. Bone marrow-derived stromal cell line expressing osteoblastic phenotype in vitro and osteogenic capacity in vivo. J Cell Physiol 1989; 140(1):1-7
5. Aronow MA, Gerstenfeld LC, Owen TA, Tassinari MS, Stein GS, Lian JB.Factors that promote progressive development of the osteoblast phenotype in cultured fetal rat calvaria cells. J Cell Physiol 1990; 143(2):213-21
6. Lomri A, Marie PJ, Tran PV,Hott M. Characterization of endosteal osteoblastic cells isolated from mouse caudal vertebrae. Bone 1988; 9(3):165-75
7. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332(5):305-11
8. Zheng MH, Wood DJ, Papadimitrion JM.What's new in the role of cytokineson osteoblast proliferation and differentiation? Pathol Res Pract 1992; 188(8):1104-21
9.童安莉,陈璐璐,丁桂芝.成骨细胞骨形成机制研究进展.中国骨质疏松杂志,1999; 5(3): 60-64
10. McCabe LR, Last TJ, Lynch M, Lian J, Stein J, Stein G Expression of cellgrowth and bone phenotypic genes during the cell cycle of normal diploid osteoblasts and osteosarcoma cells. J Cell Biochem 1994 ;56(2):274-82
11. Lynch MP, Capparelli C, Stein JL, Stein GS, Lian JB. Apoptosis during bone-like tissue development in vitro. J Cell Biochem 1998; 68(1):31-49
12. Zheng Nicholson GC, Warton A, Papadimitriou JM. What's new inosteoclast ontogeny? Pathol Res Pract 1991;187(1):117-25
13. Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K , Chesnut H 3rd. Long term calcitonin therapy in postmenopausal osteoporosis.Metabolisml 1984; 33(4):295-303
14. Barrett-Connor E. Epidemiology and the menopause: a global overview. Int JFertil Menopausal Stud 1993; 38 Suppl 1:6-14
15.李恩.原发性骨质疏松发病的相关因素.中国骨质疏松杂志,1997, 3 (2):1-3
16. Morel G , Boivin G , David L , Dubois PM , Meunier PJ. Immunocytochemical vidence for endogenous calcitonin and parathyroid hormone in osteoblasts from he calvaria of neonatal mice. Absence of endogenous estradiol and estradiol eceptors. Cell Tissue Res 1985;240(1):89-93
17. Pensler JM, Radosevich JA, Higbee R, Langman CB. Osteoclasts isolated rom membranous bone in children exhibit nuclear estrogen and progesterone eceptors. J Bone Miner Res 1990; 5(8):797-802
18.徐叔云,卞如镰主编.药理实验方法学。人民卫生出版社,1991年第二版,p1293
19. Kameda T, Mano H, Yuasa T, Mori Y, Miyazawa K, Shiokawa M, Nakamaru Y, Hiroi E, Hiura K, Kameda A, Yang NN, HakedaY, Kumegawa M. Estrogeninhibits bone resorption by directly inducing apoptosis of the bone-resorbing steoclasts. J Exp Med 1997 , 18 ; 186(4):489-95
20.任莉,陈阳生,催翠云.骨质疏松症的药物治疗.中国骨质疏松杂志2005,11(1):126-9
21. Rossouw J.E., Anderson GL., Prentice R.L. et al., Risks and benefits of strogen plus progestin in healthy postmenopausal women: principal results from he women's health initiative randomized controlled trial. J Am Med Assoc 2002;( 288):321-33
22. Elisabeth Sornay-Rendu, Patrick Garnero, Franc, Oise Munoz, Franc, ois uboeuf , Pierre D. Delmas. Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study. Bone 2003; 33(1):159-66
23. Boukes FS, Groeneveld, assendelft WJ. Summary or the DCGP practiceguideline "the menopause". Ned Tijdschr Geneeskd 2002 ; 146(28):1317-20
24. Neves-e-Castro M, Samsioe C, Dorm M, O Skouby S; European Menopause&Andropause Society. Results from WHI and HERS II一Implications for women and the prescriber of HRT. Maturitas 2002; 42(4):255-258
25.林华.骨质疏松临床治疗的选择与实施-骨质疏松的个体化治疗.国外医学内分泌学分册,2003,23 C2): 101-103
26.朱静芬,谢庆文,杨永彬.绝经后骨质疏松症药物预防和治疗方案分析.中国临床康,2005, 9 (11): 148-149
27. Alexandersen P, Toussaint A, Christiansen C, Devogelaer JP, Roux C,Fechtenbaum J, Gennari C, Reginster JY; Ipriflavone Multicenter European Fracture Study. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA 2001; 285(11):1482-8
28. Sogaard CH, Mosekilde L, Schwartz W, Leidig C; Minne HW, Ziegler R.Effects of fluoride on rat vertebral body biomechanical competence and bone mass. Bone 1995;16(1):163-9
29. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;3 59(9322): 2018-2026
30. Dambacker,Schacht(朱汉民译).骨质疏松和活性维生素D进展.Dasle, Switzerland: EULAR publisher,1996
31.谭世桥,唐晓红钙剂在绝经后骨质疏松防治中的作用,中国临床康复,2004,8(3):541
32. Sairanen S, Karkkainen M, Tahtela R, Laitinen K, Makela P,Lamberg-Allardt C, Ualimaki MJ. Bone mass and markers of bone and calcium metabolism in postmenopausal women treated with 1 , 25-dihydroxy vitamin D for four years. Calcif Tissue Int 2000; 67(2): 122-7
33. Raisz LG Bone cell biology: new approaches and unanswered queations. J Bone Miner Res 1993; 8 (Suppl 2): 5457-65
34. Santell RC, Chang YC, Nair Mq Helferich WG Dietary genistein exerts estrogenic effects upon the uterus , mammary gland and the hypothalamic/pituitary axis in rats. J Nutr 1997; 127(2):263-9
35. Anthony MS,Clarkson TB, Hughes CL. Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal rhesus monkeys. J Nutri 1996; 126(1):43-50
36. Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW Jr. Soy protein and isoflavones: their effects on blood lipids and bone density in. Am J Clin Nutri 1998; 68(6 suppl):1375S-9S
37. Naaz A, Yellayi S, Zakroczymski MA, Bunick D, Doerge DR, Lubahn DB, Helferich Wq Cooke PS. The soy isoflavone genistein decreases adipose deposition in mice, Endocrinology 2003; 144 (8):3315-20
38. Sirtori CR,Lovati MR,Manzoni C. Soy and cholesterol resuction: clinical experience. JNutr 1995; 125(3suppl):5985-6055
39. Kanazawa T,Osanai T,Zhang Xs.Protective effects of soy protein on the peroxidizability of lipoproteins in cerebro-vascular diseases.Nutr 1995;125 (3 suppl):6395-46S
40. Fotsis T, Pepper M, Adlercreutz H. Genistein a dietaryderived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 1993; 90(7): 2690-4
41. Murphy CT, Kellie S, Westwick J. Tyrosine-Kinase activity in rabbit platelets stimulated with platelet-activating factor: The effect of inhibiting tyrosine kinase with genistein on platelet-signal-molecule elevation and function responses. Eur J Biochem 1993; 216(2):639-51
42. Blair HC, Jordan SE, Peterson TC} Barnes S. Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats. J cell Biochem 1996; 61(4):629-637
43. Fanti P, Monier-Faugere MC, Geng Z, Schmidt J, Morris PE, Cohen D, Malluche HH.The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats. Osteoporos Int 1998; 8(3):274-81
44. Yamaguchi M, Sugimoto E. Stimulatory effect of genistein and daidzein on protein synthesis in osteoblastic MC3T32E1 cells: activation of amino acyl tRNA synthetase. Mol Cell Biochem 2000; 214(122): 97-102
45. Mori M, Aizawa T, Tokoro M, Mild T, Yamori Y Soy isoflavone tablets reduce osteoporosis risk factors and obesity in middle-aged Japanese women. Clin Exp Pharmacol Physiol 2004; 31(suppl 2): 539-41
46. Gikas PD, Mokbel K. Phytoestrogens and the risk of breast cancer: a review of the literature. Int J Fertil Womens Med 2005; 50(6):250-258
47. Guo JM, Xiao BX, Liu DH, Grant M, Zhang S, Lai YF, Guo YB, Liu Q.Biphasic effect of daidzein on cell growth of human colon cancer cells. Food Chem Toxicol 2004; 42(10):1641-6
48. Wangen KE, Duncan AM, Merz-Demlow BE. Effects of soy isoflavones on markers of bone turnover in premenopausal and post menopausal women. Clin Endocr 2000; 85(9): 3043-3048
49. Branca F. Dietary phyto-oestrogens and bone health. Proc Nutr Soc 2003; 62(4): 877-87
50.谢煌,姚珍薇.维生素K、雌激素和骨质疏松实用老年医学,2006, 20(5):347-349
51. IshimiY Arai N, Wang X, Wu J, Umegaki K, Miyaura C, Takeda A, Ikegami S. Difference in effective dosage of genistein on bone and uterus in ovariectomized mice. Biochem Biophys Res Commun 2000; 274(3):697-701
52. Naaz A, Yellayi S, Zakroczymski MA, Bunick D, Doerge DR, Lubahn DB,Helferich Wq Cooke PS. The soy isoflavone genistein decreases adipose deposition in mice. Endocrinology. 2003; 144(8):3315-20
53. Alekel DL, Germain AS, Peterson CT. Isoflavoen-rich soy protein isolate attenuates bone loss in lumbar spine of perimenopausaol women. Am J Clin Nutr 2000; 72(3): 844-852
54. Morabito N, Crisafulli A, Vergara C, Gaudio A, Lasco A, FrisinaN, D'Anna R, Corrado F, Pizzoleo MA, Cincotta M, Altavilla D, Ientile R, Squadrito F. Effects of genistein and hormone-replacement therapy on bone loss n early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res 2002 ; 17(10):1904-12
55. Chiechi LM, Secreto qD'Amore M, Fanelli M, Venturelli E, Cantatore F, Ualerio T, Laselva C; Loizzi P. Efficacy of a soy rich diet in preventing postmenopausal osteoporosis:the menfis randomized trial. Maturitas 2002; 42(4):295-300
56. Dalais FS, Ebeling PR, Kotsopoulos D, McGrath BP, Teede HJ. The effects of soy protein containing isoflavones on lipids and indices of bone resorption in post-menopausal women. Clin Endocrinol (Oxf) 2003; 58(6):704-9
57. Gronwald W,Schomburg D,Harder MP,et al. Structure of re2 combinant human parathyroid hormone in solution using multidi2 mensional NMR spectroscopy [J] . Biol Chem Hoppe Seyler,1996,377 (3):175
58. Schievano E,Mammi S,Silvestri L,et al.Conformational studies of parathyroid hormone ( PTH) / PTH 2related protein(PTHrP) chimeric peptides [J] . Biopolymers,2000,54 ( 7):429
59. 0ldenburg KR,Epand RF,Dorfani A,et al . Conformational studies on analogs of recombinant parathyroid hormone and their interations with phospholipids[ J] . Biolchem,1996,271 (299) :17582
60. Reidhaar Olson J F,Davis RM,De Souza Hart JA,et al.Active variants of human parathyroid (1234) with multiple amino acid substitutions[J].Mol Cell Endocri nol,2000,160 (122):135
61. Schwietert HR,Groen EW, Sollie FA,et al. Single2does sub2 cutaneousadministration of recombinant humanparathyorid hor2 mone [rhPTH(1～84)] in healthy postmenopausal volunteers[J].Cli nical Pharmacology and Therapeutics ,1997 ,61(3) :360
62. Boly J J.Gaich G A,Scheele W H,et al.A randomized doubleblind trial to compare the efficacy of teriparatide(PTH1-34) with alendronate in postmenopausal women with osteoporosis[J].J Clin Endlocrinol Metab,2002,87(10):4528
63. Urena P,Kong XF ,Abou-Samra AB, et al .Parathyroid hormone (PTH)/PTH-related peptidereceptor messenger ribonucleic acids are widely distributed in rat tissues[J].Endocrinology,1993,133:617-623
64. Perry HM 3rd, Chappel JC,Bellorin-Font E,et al. Parathyroid hormone receptors in circulating human mononuclear leukocytes[J].J Biol Chem,1984,259:5531-5535
65. Khafif A,Pivoarov A,Medina JE,et al .Parathyroid hormone:A sensitive predictorof hypocalcemia following total thyroidectomy[J]. Otolaryngol Head Neck Surg,2006,134:907-910.
66. Yu XP,Chandrasekhar S.Parathyroid hormone(PTH1–34) regulation OC of rat gene transcription[J].J Endocrinology,1997,138:3085-3092
67.洪燕,程义勇,张月红,等.钙缺乏对大鼠骨骼发育的影响及其机制探讨[J].卫生研究,2002,31:41-43
68. John T Potts. Parathyroid hormone: past and present[J]. Endocrinology,2005,187,311-325
69. Okazaki R,Inoue D,Shibata M, et al. Estrogen promotes early osteoblast differentiation and inhibits adipocyte differentiation in mouse bone marrow stromal cell lines that express estrogen receptor (ER) alpha or beta. Endocrinology. 2002 Jun;143(6):2349-2356
70.李凤英,王锦.甲状旁腺激素与骨质疏松,天津医科大学学报.2000,6(2):246-248
71. Urena P.Kong XF,Abous-Samra AB,et a1.Parathyoid hormone(PTH)/PTH-related peptidereceptor messenger ribonucleic acid are widely distributed in rattissue.Endocrinology,1993,133:6l7-623
72.徐进,荣海钦,季虹等.甲状旁腺激素相关蛋白治疗去卵巢大鼠骨质疏松的实验研究,中华风湿病杂志,2006, 10(3):154-157
73.王莹,杨淑霞.小鼠毛发周期中甲状旁腺激素受体mRNA表达的研究,中华皮肤科杂志.2002,35(2):147-148
74. Yokose S,Ishizuya T,Ikeda T,et al.An estrogen deficiency caused by ovariectomy increases plasma levels of systemic factors that stimulate proliferation and differentiation of osteoblasts in rats.Endocrinology,1996,137(2) : 469-478
75. Miao D, He B, Karaplis AC, Goltzman D,et al. Parathyroid hormone is essential for normal fetal bone formation. J Clin Invest. 2002 May;109(9):1173-1182
76. Schipani E,Karga H,Karaplis A C,et al. Identical complementary deoxyribonucleic acids encode a human renal and bone parathyroid hormone (PTH)/PTH-related peptide receptor. Endocrinology. 1993; 132: 2157-2165
77. Schipani E, Langman C, Hunzelman J, et al. A novel parathyroid hormone (PTH)/PTH-related peptide receptor mutation in Jansen's metaphyseal chondrodysplasia. J. Clin. Endocr. Metab. 1999 ; 84: 3052-3057
78. Parfitt A M,Schipani E,Rao D S,et al. Hypercalcemia due to constitutive activity of the parathyroid hormone (PTH)/PTH-related peptide receptor:comparison with primary hyperpara-thyroidism. J. Clin. Endocr. Metab. 1996; 81: 3584-3588
79. Jobert A-S,Zhang P, Couvineau A, et al. Absence of functional receptors for parathyroid hormone and parathyroid hormone-related peptide in Blomstrand chondrodysplasia. J. Clin. Invest.1998;102: 34-40
80. Hopyan S,Gokgoz N,Poon R,et al. A mutant PTH/PTHrP type I receptor in enchondromatosis. Nature Genet. 2002;30: 306-310